Paul C Guest PhD
Head of Proteomics
My main focus over the past 10 years has been on the application of proteomic technologies in discovery of biomarkers for neurological and neurodegenerative diseases. I have emphasized an approach that includes the application of multiple technologies to maximize proteomic coverage and the use of supportive methods for validation and rapid deployment of markers into the laboratory or the clinical environment.
My scientific career began in California in 1983 with the production of immunoassay kits at Dakopats Corporation and in 1984 on development of transgenic crop plants at the Plant Cell Research Institute and eradication of plant cell viruses for Universal Foods. In 1985, I carried out studies on modulating the TPA cleavage site at Genentech. Then in 1986, I worked on characterization of the coral toxin and reptile venom binding site of the nicotinic acetylcholine receptor at University of California, San Diego. In 1988, I began my PhD work at the University of Cambridge, UK, with a thesis entitled "Insulin Secretory Granule Biogenesis."
In 1991, I was awarded the RDA Lawrence fellowship for diabetes research to continue these studies, beginning of my interest in proteomics (3 years before the term was coined). In 1995, I carried out further related studies using mRNA differential display to identify gene products involved in the biogenesis of neuroendocrine secretory vesicles. In 1997, I began working at the Merck Neuroscience Research Centre in the UK, where I set up and headed the proteomics core facility. We carried out proteomic and transcriptomic analysis on proof of principle, target validation and biomarker identification phases of drug discovery for neurological and neurodegenerative diseases and for potential stem cell therapies. We brought in and developed new proteomic approaches and used immunological techniques and other methods to validate biomarkers and to transfer these to a format where they could be easily deployed in the laboratory or the clinic.
In 2007, I began as Head of Proteomics in the Bahn lab at the CCNR. The lab is focused on identifying and developing biomarkers for schizophrenia and other neurological disorders to improve our understanding of the molecular basis of these diseases, to facilitate early and accurate diagnoses and development of novel therapeutic strategies.
Hassan Rahmoune PhD
Head of Translational Medicine & Discovery Biomarkers
I obtained my Doctorate in Biochemistry at Lille University, France. Since that time I amassed an extensive expertise in a number of therapeutic areas (Respiratory, Oncology, Diabetes and Neuropsychiaric diseases) with the main focus on translational medicine and discovery biomarkers.
I set up and headed the biomarker discovery facility at the GlaxoSmithKline Cambridge Clinical Research Unit. In my role, I was heading a group of scientists responsible for designing and running fit-for-purpose laboratory and experimental medicine studies related to biomarker discovery in diabetes, cardiovascular diseases and mental disorders. The outcome of such studies was included into clinical protocols and validated in a phase I-II clinical studies. As part of clinical matrix teams, I was also responsible for bio-sampling procedures and introducing and managing biomarker analysis/arms into clinical protocols of phase I-II clinical trials.
I joined the Bahn lab in 2008 as the Head of Translational Medicine & Biomarker Discovery and as consultant to Psynova Neurotech Ltd. My main focus is on identifying a panel of diagnostic, prognostic biomarkers and novel targets related to neuropsychiatric disorders and translating these from laboratory to clinic development.
Jason Cooper PhD
Head of Statistics
I have worked as a statistician for about 20 years (University of Warwick,
MRC Biostatistics Unit and University of Cambridge). I joined the Bahn lab
in 2013, where, in conjunction with other members of the group, I apply
statistical methods to biological datasets to understand the mechanisms
underlying major neuropsychiatric disorders.
Man Kuan Chan PhD
I hold a BSc (Hons) degree in Medical Genetics (Brunel University, 2005) and a PhD in neuroscience/biotechnology (University of Cambridge, 2009, Professor Bahn's group). My research direction since industrial work placement at GSK (2003-2004), PhD and post-doctoral work (2009-2010) at Professor Bahn's group has been focused on biomarker discovery, drug-target identification and translational research in neuropsychiatric disorders. During these years, I have developed solid skills in clinical tissue proteomics and metabonomics profiling, bioinformatics, analytical and molecular cell biology methodologies and pre-clinical model development. Currently, I am working towards identifying predictive cellular/molecular markers of drug response, symptom improvement and/or non-improvement in depression patients in a longitudinal study.
Sureyya Ozcan PhD
I am a bioanalytical chemist specialing in mass spectrometry with clinical, biological, nutritional and pharmacological applications. I hold a BSc degree (Gazi University, Turkey) and PhD degree in Chemistry (University of California, Davis, USA). My research interest is developing Mass Spectrometry based tools for the discovery of diagnostic and prognostic disease markers. I primarily use an `OMICS` approach; Glycomics, Glycoproteomics and Proteomics to unravel the complexity of biological systems. I am also interested in developing protocols for the characterization of glycans. glycoproteins and therapeutics.
Tillmann Ruland MD
I have always been fascinated by the interaction of different systems in the human body during health and disease. Therefore I studied medicine. After I graduated from medical school in 2010, Muenster, Germany, I started working at the University Hospital Department of Psychiatry and Psychotherapy in Muenster. I worked with patients suffering from treatment resistant affective disorders and I joined the Zwanzger group. In the group I was involved in projects studying molecular changes during anxiety by using magnetic resonance spectroscopy. In 2013, as part of the PSYCH-AID Marie Curie project, I got the opportunity to join the Bahn lab. My aim is to learn more about proteomics and biomarker development and to develop biomarkers which predict response to therapy.
Pawel Stocki PhD
Senior Scientist at Psynova Neurotech Ltd
During my 10 year scientific career I have been involved in a number of multidisciplinary research projects, spanning from protein biochemistry to cell biology to immunology. I hold an MSc in Biotechnology from the University of Gdansk (Poland) and a PhD in Cellular Medicine from Newcastle University (UK) plus 3 years of post-doctoral experience in biochemistry and cell biology from the University of Toronto (Canada). This required me to master a wide variety of techniques while working in the fields of basic research as well as translational clinical studies.
Due to my interest in applicable and translational research, I was pleased to begin as a senior scientist at Psynova Neurotech at the beginning of 2013, leading the biomarker discovery project in the field of neuropsychiatric disorders. The project focuses on the identification of predictive biomarkers, which would allow clinicians to personalise patient’s medication and improve therapy outcome.
Paula Suarez-Pinilla MD
I obtained my MD qualification at Oviedo University, Spain (2001-2008) and trained as a psychiatrist at University Hospital Marqués de Valdecilla, Santander, Spain until 2012. I am working there as a medical doctor, combining research and clinical practice. My main focus over the past two years has been on the study of clinical, genetic and neuroanatomical aspects of patients suffering their first episode of psychosis and I was involved in longitudinal studies. In October 2013, I obtained a post residence grant from the Biomedical Research Institute Marqués de Valdecilla (IFIMAV) and received the opportunity to join the Bahn lab for one year. My aim is now to learn more about peripheral biomarkers that could provide a better understanding of the molecular basis of the early stages of schizophrenia.
Karin Weigelt PhD
I recently obtained my PhD at the department of Immunology of the Erasmus Medical Center in Rotterdam, the Netherlands. I am especially interested in the immunological aspects of psychiatric disorders. There is considerable evidence for an activated immune response system in people suffering from these conditions. Therefore, my aim within the Psych-Aid project is to identify biomarkers (both proteins and microRNAs) based on immune response system activation to facilitate early and accurate diagnosis and the prediction of drug response.